{"success":true,"data":{"pressRelease":{"id":"2747","rtpr_id":"nGNX2f4X7","ticker":"CELU","exchange":"NASDAQ","all_tickers":["CELU","CELUW"],"title":"Celularity Announces Closing of Transaction with NexGel","author":"Globe Newswire","published_at":"2026-04-21T12:30:00.822Z","article_body":"FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc.\n(Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and\ncellular medicine company, today announced the closing of its previously\nannounced transaction with NexGel, Inc. (“NexGel”), pursuant to which\nNexGel acquired certain commercial and other assets related to Celularity’s\nbiomaterials product portfolio and received an exclusive license to develop\nand commercialize specified products. The transaction is intended to monetize\nCelularity’s biomaterials portfolio while enabling it to further concentrate\nresources on advancing its longevity-focused therapeutic pipeline and scalable\nmanufacturing platform.\n\nUnder the terms of the transaction, Celularity received aggregate\nconsideration of $13.3 million, consisting of $8.3 million in cash at closing\nand a $5.0 million convertible promissory note from NexGel. In addition,\nCelularity remains eligible to receive up to $20.0 million in future milestone\npayments based on net sales thresholds, and royalties on net sales of certain\ndevelopment-stage products, in each case subject to the terms of the\ntransaction documents. The transaction also enabled Celularity to retire\nnearly $13.0 million of debt, strengthening Celularity’s balance sheet and\ncapital position while preserving future economic participation in certain\nlicensed development-stage programs.\n\n“This transaction with NexGel marks an important step in Celularity’s\nongoing efforts to sharpen strategic focus, monetize non-core biomaterials\nassets and strengthen Celularity’s capital position as we advance our\nlongevity-focused strategy,” said Robert J. Hariri, M.D., Ph.D.,\nCelularity’s Founder, Chairman and Chief Executive Officer. “By\nstreamlining our biomaterials activities while retaining the opportunity to\nparticipate in future milestone and royalty economics, we are further aligning\nresources around high-value cellular therapeutics and other programs targeting\nthe fundamental mechanisms of aging.”\n\nAbout Celularity\n\nCelularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and\ncellular medicine company developing and manufacturing allogeneic and\nautologous cell therapies derived from the postpartum placenta. Celularity\nleverages the placenta’s unique biology, immunologic properties, and\nscalable availability to develop therapeutic solutions targeting fundamental\nmechanisms of aging and age-related disease.\n\nFor more information, please visit www.celularity.com.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including, without\nlimitation, statements regarding the expected benefits of the transaction with\nNexGel, Celularity’s ability to receive future royalty and milestone\npayments, the anticipated balance sheet and capital position benefits of the\ntransaction, and Celularity’s strategic plans, including its\nlongevity-focused strategy, and Celularity’s ability to realize the\nanticipated strategic and financial benefits of the transaction. These\nforward-looking statements are based on current beliefs, expectations and\nassumptions and are subject to substantial risks and uncertainties that could\ncause actual results to differ materially from those expressed or implied by\nsuch statements. These risks and uncertainties include, among others, risks\nrelated to NexGel’s commercialization of the licensed products, the\nachievement of royalty and milestone thresholds, and other risks and\nuncertainties described in Celularity’s filings with the Securities and\nExchange Commission. Celularity undertakes no obligation to update any\nforward-looking statements except as required by law.\n\nInvestor Contact:\n\nCarlos Ramirez\nSenior Vice President, Celularity Inc.\nCarlos.ramirez@celularity.com\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2f4X7","title":"Celularity Announces Closing of Transaction with NexGel","author":"Globe Newswire","ticker":"CELU","created":"2026-04-21T12:30:00.822Z","tickers":["CELU","CELUW"],"exchange":"NASDAQ","article_body":"FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc.\n(Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and\ncellular medicine company, today announced the closing of its previously\nannounced transaction with NexGel, Inc. (“NexGel”), pursuant to which\nNexGel acquired certain commercial and other assets related to Celularity’s\nbiomaterials product portfolio and received an exclusive license to develop\nand commercialize specified products. The transaction is intended to monetize\nCelularity’s biomaterials portfolio while enabling it to further concentrate\nresources on advancing its longevity-focused therapeutic pipeline and scalable\nmanufacturing platform.\n\nUnder the terms of the transaction, Celularity received aggregate\nconsideration of $13.3 million, consisting of $8.3 million in cash at closing\nand a $5.0 million convertible promissory note from NexGel. In addition,\nCelularity remains eligible to receive up to $20.0 million in future milestone\npayments based on net sales thresholds, and royalties on net sales of certain\ndevelopment-stage products, in each case subject to the terms of the\ntransaction documents. The transaction also enabled Celularity to retire\nnearly $13.0 million of debt, strengthening Celularity’s balance sheet and\ncapital position while preserving future economic participation in certain\nlicensed development-stage programs.\n\n“This transaction with NexGel marks an important step in Celularity’s\nongoing efforts to sharpen strategic focus, monetize non-core biomaterials\nassets and strengthen Celularity’s capital position as we advance our\nlongevity-focused strategy,” said Robert J. Hariri, M.D., Ph.D.,\nCelularity’s Founder, Chairman and Chief Executive Officer. “By\nstreamlining our biomaterials activities while retaining the opportunity to\nparticipate in future milestone and royalty economics, we are further aligning\nresources around high-value cellular therapeutics and other programs targeting\nthe fundamental mechanisms of aging.”\n\nAbout Celularity\n\nCelularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and\ncellular medicine company developing and manufacturing allogeneic and\nautologous cell therapies derived from the postpartum placenta. Celularity\nleverages the placenta’s unique biology, immunologic properties, and\nscalable availability to develop therapeutic solutions targeting fundamental\nmechanisms of aging and age-related disease.\n\nFor more information, please visit www.celularity.com.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including, without\nlimitation, statements regarding the expected benefits of the transaction with\nNexGel, Celularity’s ability to receive future royalty and milestone\npayments, the anticipated balance sheet and capital position benefits of the\ntransaction, and Celularity’s strategic plans, including its\nlongevity-focused strategy, and Celularity’s ability to realize the\nanticipated strategic and financial benefits of the transaction. These\nforward-looking statements are based on current beliefs, expectations and\nassumptions and are subject to substantial risks and uncertainties that could\ncause actual results to differ materially from those expressed or implied by\nsuch statements. These risks and uncertainties include, among others, risks\nrelated to NexGel’s commercialization of the licensed products, the\nachievement of royalty and milestone thresholds, and other risks and\nuncertainties described in Celularity’s filings with the Securities and\nExchange Commission. Celularity undertakes no obligation to update any\nforward-looking statements except as required by law.\n\nInvestor Contact:\n\nCarlos Ramirez\nSenior Vice President, Celularity Inc.\nCarlos.ramirez@celularity.com\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-21T12:30:00.856193111Z","server_sent_at_ms":1776774600856},"received_at":"2026-04-21T12:30:00.912Z","source_url":"https://www.globenewswire.com/news-release/2026/04/21/3277939/0/en/Celularity-Announces-Closing-of-Transaction-with-NexGel.html"},"analysis":{"id":"1749","press_release_id":"2747","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"m_and_a","narrative":"Celularity closed the sale of its biomaterials assets to NexGel for $13.3 million, consisting of $8.3 million in cash and a $5 million convertible note.\n\nThe company used the transaction to retire nearly $13 million in debt, strengthening its balance sheet and capital position.\n\nCelularity remains eligible for up to $20 million in future milestone payments and royalties, allowing it to concentrate resources on its longevity-focused therapeutic pipeline.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-core asset sale cleans up balance sheet and sharpens focus on longevity pipeline."},"keyFigures":{"dealValueUsd":13300000,"customDimensions":{"debt_retired":"$13.0 million","cash_at_closing":"$8.3 million","convertible_note":"$5.0 million","potential_milestones":"$20.0 million"}},"quotedText":"This transaction with NexGel marks an important step in Celularity’s ongoing efforts to sharpen strategic focus, monetize non-core biomaterials assets and strengthen Celularity’s capital position","namedEntities":{"people":[{"name":"Robert J. Hariri","role":"Founder, Chairman and Chief Executive Officer"}],"products":["biomaterials product portfolio"],"companies":[{"name":"NexGel, Inc.","relationship":"acquirer"}],"dollarAmounts":[{"amount":"$13.3 million","context":"aggregate consideration received"},{"amount":"$8.3 million","context":"cash received at closing"},{"amount":"$5.0 million","context":"convertible promissory note"},{"amount":"$20.0 million","context":"future milestone payments"},{"amount":"$13.0 million","context":"debt retired"}]},"materialImpact":{"score":3,"reasoning":"The transaction monetizes non-core assets for $13.3 million and retires nearly $13 million in debt, significantly strengthening the balance sheet and sharpening strategic focus, though it is not a transformative merger or binary regulatory event."},"tickerRelevance":{"others":[],"primary":"CELU"},"eventTypeSecondary":[]},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Celularity closed the sale of its biomaterials assets to NexGel for $13.3 million, consisting of $8.3 million in cash and a $5 million convertible note.\n\nThe company used the transaction to retire nearly $13 million in debt, strengthening its balance sheet and capital position.\n\nCelularity remains eligible for up to $20 million in future milestone payments and royalties, allowing it to concentrate resources on its longevity-focused therapeutic pipeline.","key_figures":{"dealValueUsd":13300000,"customDimensions":{"debt_retired":"$13.0 million","cash_at_closing":"$8.3 million","convertible_note":"$5.0 million","potential_milestones":"$20.0 million"}},"named_entities":{"people":[{"name":"Robert J. Hariri","role":"Founder, Chairman and Chief Executive Officer"}],"products":["biomaterials product portfolio"],"companies":[{"name":"NexGel, Inc.","relationship":"acquirer"}],"dollarAmounts":[{"amount":"$13.3 million","context":"aggregate consideration received"},{"amount":"$8.3 million","context":"cash received at closing"},{"amount":"$5.0 million","context":"convertible promissory note"},{"amount":"$20.0 million","context":"future milestone payments"},{"amount":"$13.0 million","context":"debt retired"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T16:33:48.674Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.393Z"}},"durationMs":97358,"modelName":"glm-4.7"}}